AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACRX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.10
  • 50 Day Moving Average: $2.82
  • 200 Day Moving Average: $3.12
  • 52-Week Range: $2.40 - $4.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.82
  • P/E Growth: 0.00
  • Market Cap: $140.53M
  • Outstanding Shares: 45,333,000
  • Beta: 2.63
Profitability:
  • Net Margins: -347.94%
  • Return on Equity: -232.39%
  • Return on Assets: -36.36%
Debt:
  • Debt-to-Equity Ratio: 3.71%
  • Current Ratio: 6.24%
  • Quick Ratio: 6.15%
Additional Links:
Companies Related to AcelRx Pharmaceuticals:

Analyst Ratings

Consensus Ratings for AcelRx Pharmaceuticals (NASDAQ:ACRX) (?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $8.75 (182.26% upside)

Analysts' Ratings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Show:
DateFirmActionRatingPrice TargetDetails
12/6/2016Roth CapitalSet Price TargetBuy$15.00View Rating Details
12/5/2016HC WainwrightReiterated RatingBuy$7.00View Rating Details
11/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
10/4/2016Jefferies Group LLCReiterated RatingBuy$7.00View Rating Details
8/16/2016RBC Capital MarketsReiterated RatingPositive$6.00View Rating Details
8/5/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
5/6/2016Seaport Global SecuritiesUpgradeAccumulate -> BuyView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageNeutralView Rating Details
10/30/2015Royal Bank Of CanadaLower Price Target$7.00 -> $6.00View Rating Details
5/6/2015MizuhoReiterated RatingNeutral$5.50 -> $3.00View Rating Details
3/10/2015JMP SecuritiesLower Price TargetMarket Outperform$12.00 -> $8.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/1/2016Q316($0.23)($0.25)$2.89 million$1.60 millionViewN/AView Earnings Details
7/28/2016Q216($0.22)($0.24)$2.17 million$4.53 millionViewListenView Earnings Details
5/2/2016Q1($0.20)($0.24)$1.62 million$1.80 millionViewListenView Earnings Details
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details
8/3/2015Q215($0.26)($0.20)ViewListenView Earnings Details
5/4/2015Q115($0.28)($0.27)ViewN/AView Earnings Details
3/9/2015($0.33)($0.32)ViewN/AView Earnings Details
8/11/2014Q214($0.26)($0.24)$40.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.23)($0.22)ViewN/AView Earnings Details
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.19)($0.26)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.41 millionViewListenView Earnings Details
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Current Year EPS Consensus Estimate: $-0.98 EPS
Next Year EPS Consensus Estimate: $-1.10 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.31)($0.19)($0.25)
Q2 20162($0.28)($0.23)($0.26)
Q3 20162($0.28)($0.22)($0.25)
Q4 20162($0.27)($0.27)($0.27)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Insider Ownership Percentage: 27.40%
Institutional Ownership Percentage: 35.01%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2016Perceptive Advisors LlcMajor ShareholderSell216,500$3.92$848,680.00View SEC Filing  
9/15/2016Perceptive Advisors LlcMajor ShareholderSell392,850$3.70$1,453,545.00View SEC Filing  
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.56View SEC Filing  
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00View SEC Filing  
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateHeadline
News IconWhat the Technicals Are Saying About AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Midway Monitor (NASDAQ:ACRX)
midwaymonitor.com - February 22 at 8:21 PM
News IconTechnical Trading: Focus on Shares of AcelRx Pharmaceuticals Inc (ACRX) - Davidson Register (NASDAQ:ACRX)
davidsonregister.com - February 22 at 11:44 AM
News IconAnalysts Peer Into Their Crystal Balls For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX): Where Is It headed? - Winfield Review (NASDAQ:ACRX)
winfieldreview.com - February 22 at 11:44 AM
News IconSell-side is Weighing in on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Earnings & Targets - Aiken Advocate (NASDAQ:ACRX)
aikenadvocate.com - February 21 at 5:45 AM
streetinsider.com logoAcelRx Pharma (ACRX) Names Vincent J. Angotti as CEO - StreetInsider.com (NASDAQ:ACRX)
www.streetinsider.com - February 18 at 3:17 PM
streetinsider.com logoAcelRx Pharma (ACRX) Names Vincent J. Angotti as CEO (NASDAQ:ACRX)
www.streetinsider.com - February 16 at 8:24 PM
us.rd.yahoo.com logoAcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer (NASDAQ:ACRX)
us.rd.yahoo.com - February 16 at 8:24 PM
us.rd.yahoo.com logo4:46 pm AcelRx appoints Vincent Angotti Chief Executive Officer (NASDAQ:ACRX)
us.rd.yahoo.com - February 16 at 8:24 PM
biz.yahoo.com logoACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ACRX)
biz.yahoo.com - February 16 at 8:24 PM
biz.yahoo.com logoACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ACRX)
biz.yahoo.com - February 16 at 8:24 PM
feeds.benzinga.com logoExclusive: AcelRx Pharma Execs Discuss Stock Performance, Catalysts And Financial Position (NASDAQ:ACRX)
feeds.benzinga.com - February 16 at 1:42 PM
benzinga.com logoAcelRx: Replacing Morphine With Department Of Defense Funding (NASDAQ:ACRX)
www.benzinga.com - February 16 at 6:31 AM
News IconTechnical Roundup on Shares of AcelRx Pharmaceuticals Inc. (ACRX) - Baldwin Journal (NASDAQ:ACRX)
baldwinjournal.com - February 13 at 3:23 PM
streetinsider.com logoAcelRx Pharma (ACRX) Announces Presentation of Comprehensive Results from DSUVIA SAP302 Study - StreetInsider.com (NASDAQ:ACRX)
www.streetinsider.com - February 13 at 3:23 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain (NASDAQ:ACRX)
finance.yahoo.com - February 13 at 3:23 PM
finance.yahoo.com logo7:16 am AcelRx will present results from the DSUVIA SAP302 study of patients at the JAB Burn and Wound Care Symposium on February 12-16 (NASDAQ:ACRX)
finance.yahoo.com - February 13 at 3:23 PM
marketexclusive.com logoACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Departure of Directors or Certain Officers; Election ... - Market Exclusive (NASDAQ:ACRX)
marketexclusive.com - February 10 at 3:22 PM
biz.yahoo.com logoACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:ACRX)
biz.yahoo.com - February 9 at 8:21 PM
News IconStock Radar: Viewing Levels for AcelRx Pharmaceuticals Inc. (ACRX) - Piedmont Register (NASDAQ:ACRX)
piedmontregister.com - February 8 at 3:23 PM
nasdaq.com logoAcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3% - Nasdaq (NASDAQ:ACRX)
www.nasdaq.com - February 7 at 3:24 PM
prnewswire.com logoAcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February - PR Newswire (press release) (NASDAQ:ACRX)
www.prnewswire.com - February 7 at 3:24 PM
finance.yahoo.com logoAcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February (NASDAQ:ACRX)
finance.yahoo.com - February 7 at 3:24 PM
News IconStock Finding Its Footing and Climbing Higher: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Aiken Advocate (NASDAQ:ACRX)
aikenadvocate.com - February 6 at 3:22 PM
News IconCCI Focus on Shares of AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - February 3 at 3:24 PM
News IconMA Levels in Review for AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - February 2 at 8:21 PM
News IconOn the Hunt For the Next Wonder Stock: Penny Stock AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Nelson Research (NASDAQ:ACRX)
nelsonobserver.com - February 1 at 3:23 PM
News IconInvestor Guide: Check on Technical Levels for AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - February 1 at 3:23 PM
News IconKeeping an Eye on Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - The Tribune (NASDAQ:ACRX)
lakecitytribune.com - January 31 at 8:24 PM
News IconChart Inspection on Shares of AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 31 at 3:23 PM
News IconCan This Stock Gain Traction: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Prospect Journal (NASDAQ:ACRX)
prospectjournal.com - January 30 at 8:32 PM
News IconIs This Stock Capable of a Bull Run: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Nelson Research (NASDAQ:ACRX)
nelsonobserver.com - January 30 at 3:29 PM
News IconInvestor Focus on Technical Levels for AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 30 at 3:29 PM
News IconOff To a Slow Start in The New Year, Stock Looks For a Turnaround: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Aiken Advocate (NASDAQ:ACRX)
aikenadvocate.com - January 28 at 3:19 PM
investornewswire.com logoAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Records An Impact Score Of 50 - Investor Newswire (NASDAQ:ACRX)
www.investornewswire.com - January 28 at 3:19 PM
News IconWatching Technical Positions on AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 27 at 3:42 PM
News IconInvestor Watch: Volatility Review for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - The Tribune (NASDAQ:ACRX)
lakecitytribune.com - January 27 at 1:37 AM
News IconInvestor Corner: Checking in on Shares of AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 26 at 3:33 PM
News IconEarnings in Full Force, Analysts Take Aim at AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Wall Street Beacon (NASDAQ:ACRX)
wsbeacon.com - January 26 at 3:33 PM
News IconMarching to the Beat of Their Own Drum, Update on AcelRx ... - Prospect Journal (NASDAQ:ACRX)
prospectjournal.com - January 26 at 1:28 AM
News IconWatching the Technicals on Shares of AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 25 at 3:23 PM
News IconChart Level Analysis on Shares of AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 24 at 8:39 PM
News IconInvestor Update: Tracking Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - The Tribune (NASDAQ:ACRX)
lakecitytribune.com - January 24 at 3:38 PM
News IconWhat are Brokerage Firms Saying About AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)? - Aiken Advocate (NASDAQ:ACRX)
aikenadvocate.com - January 24 at 1:23 AM
News IconTrading Insight: Taking a Look at Levels for AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 23 at 3:20 PM
News IconFocus on RSI and CCI Levels: AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 20 at 8:26 PM
News IconIndicator Level Review for AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 19 at 3:31 PM
News IconAre Discerning Investors Interested in These Shares: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Prospect Journal (NASDAQ:ACRX)
prospectjournal.com - January 19 at 3:31 PM
News IconNear-Term, Can This Stock Move the Needle: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Prospect Journal (NASDAQ:ACRX)
prospectjournal.com - January 19 at 1:56 AM
News IconInvestor Guide: Checking on Indicators for AcelRx Pharmaceuticals Inc. (ACRX) - Sherwood Daily (NASDAQ:ACRX)
sherwooddaily.com - January 18 at 3:47 PM
News IconToday's Rating Sentiment Change: Are Analysts Bearish AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) After Last Week? - Fair View Times (NASDAQ:ACRX)
fairviewtimes.com - January 18 at 3:47 PM

Social

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Where is AcelRx Pharmaceuticals' stock going? Where will AcelRx Pharmaceuticals' stock price be in 2017?

8 analysts have issued twelve-month target prices for AcelRx Pharmaceuticals' stock. Their predictions range from $6.00 to $15.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $8.75 in the next year.

When will AcelRx Pharmaceuticals announce their earnings?

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:

  • According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (2/7/2017)

  • Cowen and Company analysts commented, "AcelRx announced the advancement of ARX-04 into a multi-dose expansion phase of." (3/14/2016)

Who owns AcelRx Pharmaceuticals stock?

AcelRx Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (11.93%), Palo Alto Investors LLC (2.28%), State Street Corp (1.08%), Oxford Asset Management (0.23%) and GRT Capital Partners L.L.C. (0.11%). Company insiders that own AcelRx Pharmaceuticals stock include Howard B Rosen, Mark G Edwards and Perceptive Advisors Llc.

Who sold AcelRx Pharmaceuticals stock? Who is selling AcelRx Pharmaceuticals stock?

AcelRx Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC and GRT Capital Partners L.L.C..

Who bought AcelRx Pharmaceuticals stock? Who is buying AcelRx Pharmaceuticals stock?

AcelRx Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Oxford Asset Management and State Street Corp. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Howard B Rosen and Mark G Edwards.

How do I buy AcelRx Pharmaceuticals stock?

Shares of AcelRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AcelRx Pharmaceuticals stock cost?

One share of AcelRx Pharmaceuticals stock can currently be purchased for approximately $3.10.

AcelRx Pharmaceuticals (NASDAQ:ACRX) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Earnings History Chart

Earnings by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Dividend History Chart

Dividend Payments by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Last Updated on 2/22/2017 by MarketBeat.com Staff